Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24741504 | 1.00 | LPL (0.38) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL15096664 | 0.88 | LIPG (0.42) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL19585777 | 0.84 | CYP1A2 (0.43) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL17553496 | 0.84 | OPRK1 (0.49) | CA1CA2CA9 | |
| SCHEMBL31371915 | 0.82 | DRD2 (0.47) | LPLLIPG | |
| SCHEMBL29502333 | 0.81 | LPL (0.47) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL16639375 | 0.81 | LPL (0.47) | LPLLIPGBACE1ROCK1CA1 | |
| SCHEMBL15854890 | 0.80 | LIPG (0.41) | LPLLIPGROCK1CA1CA2 | |
| SCHEMBL12728113 | 0.79 | HTR1D (0.40) | LPLLIPGBACE1ROCK1 | |
| SCHEMBL30284869 | 0.78 | LPL (0.44) | LPLLIPGBACE1ROCK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114601-A1 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110223132-A1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114601-A1 | NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | TOP1, RECQL, IRF3 | LPL 4865/4885LIPG 4757/4885BACE1 4432/4885 |
| US-20110223132-A1 | ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS | TOP1, IRF3, RECQL | LPL 4856/4885LIPG 4733/4885BACE1 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.